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Weighing the Risks of Target
Vessel Revascularization
Versus Very Late Stent
Thrombosis in
Primary Percutaneous
Coronary Intervention*
Eric R. Bates, MD
Ann Arbor, Michigan
Compared with fibrinolytic therapy for ST-segment eleva-
tion myocardial infarction (STEMI), primary percutaneous
coronary intervention (P-PCI) reduces the risk of reinfarc-
tion and improves survival (1). Adding bare-metal stent
(BMS) implantation after balloon angioplasty reduces re-
occlusion and restenosis rates, with drug-eluting stent
(DES) implantation further decreasing the risk of restenosis
and target lesion revascularization (TVR) (2). Unfortu-
nately, there is a higher risk of very late stent thrombosis
(ST) when first-generation DES (sirolimus-eluting or
paclitaxel-eluting stents) are used instead of BMS, and this
seems to be greater in patients with STEMI compared with
stable ischemic heart disease (2,3). Stent thrombosis with
DES is presumably due to delayed healing from chronic
inflammation, persistent fibrin deposition, and a greater
number of uncovered or malapposed stent struts compared
with BMS (4,5).
See page 1043
In this issue of JACC: Cardiovascular Interventions, Bro-
die et al. (6) report on their single center experience with
stent thrombosis in 1,640 consecutive patients treated with
P–PCI from 1995 to 2009 and a median follow-up time of
3.7 years. The frequency of ST was relatively high and
progressively increased from 2.7% at 30 days to 5.2% at 1
year to 8.3% at 5 years. Early (30 day) and late (1 year) ST
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m, Killip Class III to IV, reperfusion time 2 h, prior
yocardial infarction (MI), and diabetes mellitus. Very late
1 year) ST was only predicted by the use of DES instead
f BMS.
This study is limited by including patients treated over a
5-year period, during which PCI technology and adjunc-
ive pharmacotherapy evolved dramatically. Also, although
MS was used in the early years, first-generation DES were
redominantly used in later years, so the cohorts were
equential rather than parallel. Moreover, only 410 of 1,640
atients were treated with DES, and follow-up was not
qual for all patients, ranging from 1 to 15 years. Dual
ntiplatelet therapy (DAPT) compliance was only 60% with
arly ST and 52% with late ST, potentially explaining some
f the events. Although this “all-comers” experience might
epresent a broader, more complex, and generalizable pop-
lation than enrolled in randomized trials addressing this
uestion, selection bias and unknown or unmeasured con-
ounders might have influenced the results.
Nevertheless, several meta-analyses support the conclu-
ion that ST progressively occurs after P–PCI with DES.
rar et al. (7) evaluated 7,352 patients from 13 randomized
rials comparing BMS and DES and found reduced TVR
ith DES without increased risk for death, MI, or ST with
p to 2-year follow-up. Additionally, 26,521 patients from
8 registry studies had similar results. However, the neutral
ffect on ST was due to the combination of lower ST rates
ith DES in the first year and higher ST rates during the
econd year. De Luca et al. (8) performed a patient-level
eta-analysis, including 6,298 patients from 11 trials fol-
owed for a mean of 3.3 years. They also found a significant
eduction in TVR without differences in cumulative mor-
ality, reinfarction, or ST, but there was an increased risk of
einfarction and ST with DES after 2 years of follow-up.
alesan et al. (9) evaluated 7,867 patients from 15 trials.
he benefit for TVR reduction with DES was greater in the
rst year, compared with subsequent years, but the small
isk reduction in ST during the first year with DES changed
o risk increase and was doubled with DES in subsequent
ears. Over 5 years, the estimated number needed to treat
ith DES to prevent 1 TVR was 15, and the number
eeded to harm to cause 1 definite ST was 111. Importantly,
one of the analyses have shown significant differences in
ate survival, perhaps because of the beneficial effects of
ES in preventing the complications of restenosis (10).
ote that the approximately 50% relative risk reduction in
VR rates with DES versus BMS in P–PCI randomized
rials might have been exaggerated by protocols that man-
ated repeat angiography to evaluate for restenosis and
esulted in TVR in asymptomatic patients. Clinically driven
VR rates are lower and less than seen with elective PCI,
erhaps because of myocardial necrosis. Importantly, ST is
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1053associated with MI and death, so reducing the incidence is
an important therapeutic goal.
Therefore, the early benefit of DES in preventing ST,
restenosis, and TVR in patients after P–PCI needs to be
weighed against the very late risk of ST when deciding
whether to implant BMS versus DES. The safety of P–PCI
with DES might be improved by considering the following
possible recommendations:
• Limit DES to subsets of patients at increased risk for
TVR, including those with diabetes mellitus, smaller
coronary arterial diameter, and longer stenosis, and use
BMS in low-risk patients. By decreasing the percentage
of patients with DES in P–PCI, the risk for ST due to
DAPT non-adherence, future surgical procedures, or
bleeding events in patients is also lowered across the
population.
• Administer an upstream 4,000-U intravenous bolus of
unfractionated heparin and a 600-mg (not 300-mg)
loading dose of clopidogrel with bivalirudin anticoagula-
tion (11).
• Implant newer-generation DES, with thinner, fracture-
resistant stent struts and improved biocompatible poly-
mers, because of lower ST rates than seen with first-
generation DES (12).
• Prescribe prasugrel or ticagrelor instead of clopidogrel,
because of lower ST rates (13,14).
• Administer at least 12 months of DAPT after P–PCI
with DES, despite recent evidence that 6 months of
therapy might be sufficient for other subgroups.
Proper patient selection, improved DES design, excellent
stent implantation technique, improved DAPT strategies,
and greater emphasis on medication adherence can maxi-
mize the benefit of P–PCI with DES. In the future,
biodegradable polymers or bioresorbable vascular scaffolds
might further reduce the risk of ST (15).
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